Glaukos Corporation (GKOS) Company Profile & Statistics

Glaukos Corporation
GKOS
(NYSE)
Open
139.01
+0.57 (+0.41%)
in:usd•As of: Nov 18, 2024 12:32 UTC -5
Open
138.37
High
139.62
Low
138.05

About Glaukos Corporation

CEO

Thomas W. Burns

Headquarters

1 glaukos way

aliso viejo, ca 92656, united states

Auditor

Ernst & Young LLP

Employees

907

Share Holders

Website

www.glaukos.com

Industry

medical specialties

Sector

health technology

Company Overview

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally.

Glaukos Corporation Statistics

Valuation Measures

Market Capitalization ²	7.67B
Enterprise Value	7.69B
Enterprise Value/EBITDA (ttm)	-80.62
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	11.38
Price to Sales (ttm)	21.18
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	76.62%
Operating Margin (ttm)	-29.59%
Profit Margin (ttm)	-41.83%
Return on Equity (ttm)	-18.99%
Return on Invested Capital (ttm)	-18.67%
Return on Assets (ttm)	-11.47%

Income Statement

Revenue (ttm)	360.35M
Revenue Per Share (ttm)	6.54
Gross Profit (ttm)	276.06M
EBITDA (ttm)³	-95.40M
Net Income Avi to Common (ttm)	-149.57M
Diluted EPS (ttm)	-3.02

Share Statistics

Beta (5Y Monthly)	1.02
52-Week Change	117.47%
S&P500 52-Week Change	29.63%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	55.14M
Dividend Yield	0.00%
Float ⁴	51.61M
% Held by Insiders	6.40%
% Held by Institutions	99.04%

Balance Sheet

Total Cash (mrq)	262.47M
Total Cash Per Share (mrq)	4.76
Total Debt (mrq)	126.47M
Total Debt/Equity (mrq)	18.92%
Current Ratio (mrq)	5.54%
Quick Ratio (mrq)	4.71%
Book Value Per Share (mrq)	12.13

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.12
Free Cash Flow (ytd)	-66.35M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Glaukos Corporation

Trade With A Regulated Broker